Go or no go? The FDA plays hardball
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
Molnupiravir’s big day draws near
Early data whet appetites ahead of the big event for one of the few remaining antiviral hopes in Covid-19.
Early Morphic data hint at a threat to Entyvio
Hopes rise that Morphic might have cracked the conundrum of oral integrin inhibitors.
Merck gets on the Treg train with Pandion buy
Merck & Co pays $1.9bn for an intriguing but early approach in autoimmune disease.
